(NASDAQ: EXAS) Exact Sciences's forecast annual revenue growth rate of 14.16% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.9%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.08%.
Exact Sciences's revenue in 2026 is $3,082,033,000.On average, 27 Wall Street analysts forecast EXAS's revenue for 2026 to be $708,622,654,520, with the lowest EXAS revenue forecast at $646,665,540,074, and the highest EXAS revenue forecast at $748,790,569,696. On average, 22 Wall Street analysts forecast EXAS's revenue for 2027 to be $796,916,279,388, with the lowest EXAS revenue forecast at $681,717,730,204, and the highest EXAS revenue forecast at $853,189,254,894.
In 2028, EXAS is forecast to generate $861,336,520,708 in revenue, with the lowest revenue forecast at $719,422,518,506 and the highest revenue forecast at $954,935,341,920.